Skip to content

Contact +44 (0) 20 7060 7474 email us

Drug Delivery

Advanced Drug Delivery Systems: New Developments, New Technologies

 

Publication Date August 2009
Publisher BCC Research
Product Type Report
Pages 176
ISBN Number not applicable
Product Code BCC00052

Price

£3,205.00
approximately: $4,853 | €3,577

pdf immediate delivery

Buy Now

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

Report Highlights

The global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and was projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period. The largest segment of the market is targeted drug delivery, which reached $50.9 billion in 2009 and is expected to increase to $80.2 billion in 2014, for a CAGR of 9.5%. Sustained-release products have the second-largest market share, with estimated sales of $36.1 billion in 2009 and $45.8 billion in 2014, for a CAGR of 4.9%.

Introduction

Study Objectives

BCC' s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for advanced drug delivery systems and its future direction, with an emphasis on newer techniques and products. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drug delivery systems, including the use of these products in therapeutic markets.

An overview of types of drug delivery systems is also examined along with sales figures over the 5 year period from 2009 to 2014. This study provides an overview of the drug delivery market, which BCC projects will grow at a compound annual growth rate (CAGR) of 7.2% over the forecast period 2009 through 2014.

The study presents market size and future trends, profiles market leaders, and analyzes factors affecting drug delivery markets and important products. The report also examines future trends in drug delivery technology, the basic principles underlying different systems, and their applications. Companies manufacturing and selling the drug delivery products are also profiled. Revenues have been broken down by the type of drug delivery systems and by different regions.

Our key objective is to present a comprehensive analysis of the current market and the future direction of the advanced drug delivery systems.

Reasons For Doing This Study

The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, patent expiries, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.

This is a very complex market, where many technologies are combined together to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained-release oral/injectable drug delivery market is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes are significant new markets.

Acquisition strategies and collaborations by companies are also covered in this report, for example, the acquisition of the Pulmonary Division of Nektar Therapeutics by Novartis. This study also discusses the strength and weaknesses of drug development market in light of the new technologies, growing competition, and changing customer needs.

Intended Audience

The report consolidates much of the information on new products and new technologies in the drug delivery industry. The study contributes to understanding market growth and decline in drug delivery market from the point of view of the manufacturer and user. This study will be of interest to manufacturers and end-users in the pharmaceutical and biotechnology industries, and to companies involved in R&D for drug delivery systems and new drugs.

Scope of The Study

This study encompasses the major types of drug delivery systems used in the health industry. BCC analyzes each technology and looks at the manufacturers, their new products, sales estimates, market projections, and some market share information. BCC analyzes the industry on a worldwide basis. Patents for drug delivery technologies are also studied by year, country, and assignee. The Food and Drug Administration (FDA) approvals for the past 5 years have been covered. New developments in this field have been examined in detail, including those that comprise a part of individual company profiles.

Methodology

Both primary and secondary research methods were used in this report. A comprehensive search of the literature was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/ biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.

Information Sources

BCC surveyed many companies to obtain data for this study. We gathered the data from these industries, spoke with officials, and consulted newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.

Contents

  • Chapter- 1: Introduction -- Complimentary
    • Study Objectives
    • Reasons for Doing This Study
    • Intended Audience
    • Scope of The Study
    • Methodology
    • Information Sources
    • about The Author
    • Related BCC Reports
    • BCC Online Services
    • Disclaimer 4
  • Chapter-2: Summary
    • Summary
    • Summary Table Global Sales for Drug Delivery Products, through 2014 ($ Billions)
    • Summary Figure Global Sales for Drug Delivery Products, 2007-2014 ($ Billions) 6
  • Chapter-3: Overview
    • Definitions
    • Need for The Dosage Forms
    • Classification of Dosage Forms According to Physical Properties
    • Gaseous Dosage Forms
    • Table 1 Gaseous Dosage Forms, Advantages and Disadvantages
    • Liquid Dosage Forms
    • Table 2 Liquid Dosage Forms, Advantages and Disadvantages
    • Semisolid Dosage Forms
    • Table 3 Semisolid Dosage Forms, Advantages and Disadvantages
    • Solid Dosage Forms
    • Table 4 Solid Dosage Forms, Advantages and Disadvantages
    • Classification of Drug Delivery According to Route of Administration
    • Topical Drug Delivery
    • Table 5 Topical Drug Delivery, Advantages and Disadvantages
    • Oral Drug Delivery
    • Table 6 Oral Drug Delivery, Advantages and Disadvantages
    • Injectable or Parenteral Drug Delivery
    • Table 7 Injectable or Parenteral Drug Delivery, Advantages and Disadvantages
    • Rectal Drug Delivery
    • Table 8 Rectal Drug Delivery, Advantages and Disadvantages
    • Nasal Drug Delivery
    • Table 9 Nasal Drug Delivery, Advantages and Disadvantages
    • Table 9 (Continued)
    • Vaginal Drug Delivery
    • Table 10 Vaginal Drug Delivery, Advantages and Disadvantages
    • Ocular Drug Delivery
    • Table 11 Ocular Drug Delivery, Advantages and Disadvantages
    • Pulmonary Drug Delivery
    • Table 12 Pulmonary Drug Delivery, Advantages and Disadvantages
    • Classification of Drug Delivery Based on Technology
    • Sustained-Release Drug Delivery
    • Table 13 Sustained-Release Delivery, Advantages and Disadvantages
    • Delayed-Release Drug Delivery
    • Table 14 Delayed-Release Delivery, Advantages and Disadvantages
    • Prodrugs
    • Table 15 Prodrugs, Advantages and Disadvantages
    • Implants and Iuds
    • Table 16 Implants and Iuds, Advantages and Disadvantages
    • Targeted Drug Delivery
    • Nanoparticles
    • Liposomes
    • Table 17 Liposomes, Advantages and Disadvantages
    • Polymers
    • Table 18 Polymers, Advantages and Disadvantages
    • Monoclonal Antibodies
    • Table 19 Monoclonal Antibodies, Advantages and Disadvantages
    • Pegylation
    • Table 20 Pegylation, Advantages and Disadvantages 24
  • Chapter-4: Regulatory Issues
    • Table 21 Fda-Approved Drugs of Various Dosage Forms (2005 to Feb 2009)
    • Table 21 (Continued)
    • Table 21 (Continued)
    • Table 22 Number of New Approvals for Drug Delivery Products in Each Year, 2005- Feb. 2009
    • Figure 1 Number of New Approvals for Drug Delivery Products in Each Year, 2005 to Feb. 2009
    • Table 23 Approved Drugs of Various Dosage Forms, through Other Agencies (2005 to Feb 2009)
    • Table 24 Recalls/ Safety Alerts for Drug Delivery Systems (2005 to Feb. 2009)
    • Table 24 (Continued)
    • Regulatory Issues (Continued) 31
  • Chapter-5: Classification of Drug Products Based on Drug Delivery Type
    • Sustained-Release Oral Dosage Forms
    • Table 25 Major Suppliers and Manufacturers of Sustained-Release Oral Dosage Forms
    • Table 25 (Continued)
    • Sustained-Release Injectable Dosage Forms
    • Table 26 Major Suppliers and Manufacturers of Sustained-Release Injectable Dosage Forms
    • Sustained-Release Topical Dosage Forms
    • Table 27 Major Suppliers and Manufacturers of Sustained-Release Topical Dosage Forms
    • Prodrugs
    • Table 28 Major Suppliers and Manufacturers of Prodrugs
    • Table 28 (Continued)
    • Implants and Iuds
    • Table 29 Major Suppliers and Manufacturers of Implants and Iuds
    • Transdermal Drug Delivery Systems
    • Table 30 Major Suppliers and Manufacturers of Transdermal Drug Delivery Systems
    • Table 30 (Continued)
    • Liposomes
    • Table 31 Major Suppliers and Manufacturers of Liposomes
    • Nanoparticles
    • Table 32 Major Suppliers and Manufacturers of Nanoparticles
    • Polymers
    • Table 33 Major Suppliers and Manufacturers of Polymers
    • Monoclonal Antibodies
    • Table 34 Major Suppliers and Manufacturers of Monoclonal Antibodies
    • Pegynology
    • Table 35 Major Suppliers and Manufacturers of Pegnology
    • Buccal Drug Delivery Systems
    • Table 36 Major Suppliers and Manufacturers of Buccal Drug Delivery Systems
    • Rectal Drug Delivery Systems
    • Table 37 Major Suppliers and Manufacturers of Rectal Drug Delivery Systems
    • Vaginal Drug Delivery Systems
    • Table 38 Major Suppliers and Manufacturers of Vaginal Drug Delivery Systems
    • Table 7 (Continued)
    • Ocular Drug Delivery Systems
    • Table 39 Major Suppliers and Manufacturers of Ocular Drug Delivery Systems
    • Table 39 (Continued)
    • Inhalation Systems
    • Table 40 Major Suppliers and Manufacturers of Inhaltion Systems
    • Table 40 (Continued) 45
  • Chapter-6: Industry Structure
    • Sustained-Release Dosage Forms
    • Sustained-Release Oral Dosage Form
    • Table 41 Shares of Manufacturers/Suppliers for Sustained-Release Oral Dosage Forms, 2008 (%)
    • Figure 2 Shares of Manufacturers/Suppliers of Sustained-Release Oral Dosage Forms, 2008 (%)
    • Sustained-Release Injectable Dosage Form
    • Table 42 Shares of Manufacturers/Suppliers for Sustained-Release Injectable Dosage Forms, 2008 (%)
    • Figure 3 Shares of Manufacturers/Suppliers of Sustained-Release Injectable Dosage Forms, 2008 (%)
    • Sustained-Release Topical Dosage Form
    • Table 43 Shares of Manufacturers/Suppliers for Sustained-Release Topical Dosage Forms, 2008 (%)
    • Figure 4 Shares of Manufacturers/Suppliers of Sustained-Release Topical Dosage Forms, 2008 (%)
    • Prodrugs
    • Table 44 Shares of Manufacturers/Suppliers for Prodrugs, 2008 (%)
    • Figure 5 Shares of Manufacturers/Suppliers of Prodrugs, 2008 (%)
    • Implants and Iuds
    • Table 45 Shares of Manufacturers for Implants and Iuds, 2008 (%)
    • Figure 6 Shares of Manufacturers of Implants and Iuds, 2008 (%)
    • Transdermal Drug Delivery Systems
    • Table 46 Shares of Manufacturers/Suppliers for Transdermal Drug Delivery Systems, 2008 (%)
    • Figure 7 Shares of Manufacturers/Suppliers of Transdermal Drug Delivery Systems, 2008 (%)
    • Targeted Drug Delivery Systems
    • Liposomes
    • Table 47 Shares of Manufacturers/Suppliers for Liposomes, 2008 (%)
    • Figure 8 Shares of Manufacturers/Suppliers of Liposomes, 2008 (%)
    • Nanoparticles
    • Table 48 Shares of Manufacturers/Suppliers for Nanoparticles, 2008 (%)
    • Figure 9 Shares of Manufacturers/Suppliers of Nanoparticles, 2008 (%)
    • Polymers
    • Table 49 Shares of Manufacturers/Suppliers for Polymers, 2008 (%)
    • Figure 10 Shares of Manufacturers/Suppliers of Polymers, 2008 (%)
    • Monoclonal Antibodies
    • Table 50 Shares of Manufacturers/Suppliers for Monoclonal Antibodies, 2008 (%)
    • Figure 11 Shares of Manufacturers/Suppliers of Monoclonal Antibodies, 2008 (%)
    • Pegnology
    • Table 51 Shares of Manufacturers/Suppliers for Pegnology, 2008 (%)
    • Figure 12 Shares of Manufacturers/Suppliers of Pegnology, 2008 (%)
    • Transmucosal Drug Delivery Systems
    • Buccal Drug Delivery Systems
    • Table 52 Shares of Manufacturers/Suppliers for Buccal Drug Delivery Systems, 2008 (%)
    • Figure 13 Shares of Manufacturers/ Suppliers of Buccal Drug Delivery Systems, 2008 (%)
    • Rectal Drug Delivery Systems
    • Table 53 Shares of Manufacturers/Suppliers for Rectal Drug Delivery Systems, 2008 (%)
    • Figure 14 Shares of Manufacturers/ Suppliers of Rectal Drug Delivery Systems, 2008 (%)
    • Vaginal Drug Delivery Systems
    • Table 54 Shares of Manufacturers/Suppliers for Vaginal Drug Delivery Systems, 2008 (%)
    • Figure 15 Shares of Manufacturers/ Suppliers of Vaginal Drug Delivery Systems, 2008 (%)
    • Ocular Drug Delivery Systems
    • Table 55 Shares of Manufacturers/Suppliers for Ocular Drug Delivery Systems, 2008 (%)
    • Figure 16 Shares of Manufacturers/Suppliers of Ocular Drug Delivery Systems, 2008 (%)
    • Inhalation Systems
    • Table 56 Shares of Manufacturers/Suppliers of Inhalation Systems, 2008 (%)
    • Figure 17 Shares of Manufacturers/Suppliers of Inhalation Systems, 2008 (%)
    • Inhalation Systems (Continued) 63
  • Chapter-7: Demand and Use
    • Table 59 Global Sales of Drug Delivery Products, through 2014 ($ Billions)
    • Figure 18 Global Sales of Drug Delivery Systems, 2007-2014 ($ Billions)
    • Table 60 Market Share of Drug Delivery Products, 2008 (%)
    • Figure 19 Market Share of Drug Delivery System, 2008 (%)
    • Sustained-Release Oral Dosage Forms
    • Market Size
    • Table 61 Global Sales of Sustained-Release Oral Dosage Forms, through 2014 ($ Millions)
    • Figure 20 Total Global Sales of Sustained-Release Oral Dosage Forms, 2007-2014 ($ Millions)
    • Market Overview
    • Sustained-Release Injectable Dosgae Form
    • Market Size
    • Table 62 Global Sales of Sustained-Release Injectable Dosage Forms, through 2014 ($ Millions)
    • Figure 21 Total Global Sales of Sustained-Release Injectable Dosage Forms, 2007-2014 ($ Millions)
    • Market Overview
    • Sustained-Release Topical Dosage Forms
    • Market Size
    • Table 63 Global Sales of Sustained-Release Topical Dosage Forms, through 2014 ($ Millions)
    • Figure 22 Total Global Sales of Sustained-Release Topical Dosage Forms, 2007-2014 ($ Millions)
    • Market Overview
    • Prodrugs
    • Market Size
    • Table 64 Total Global Sales of Prodrugs, through 2014 ($ Millions)
    • Figure 23 Global Sales of Prodrugs, 2007-2014 ($ Millions)
    • Market Overview
    • Implants and Iuds
    • Market Size
    • Table 65 Global Sales of Implants and Iuds, through 2014 ($ Millions)
    • Figure 24 Total Global Sales of Implants and Iuds, 2007-2014 ($ Millions)
    • Market Overview
    • Transdermal Drug Delivery
    • Market Size
    • Table 66 Global Sales of Transdermal Drug Delivery Systems, through 2014 ($ Millions)
    • Figure 25 Total Global Sales of Transdermal Drug Delivery Systems, 2007-2014 ($ Millions)
    • Market Overview
    • Liposomes Drug Delivery
    • Market Size
    • Table 67 Global Sales of Liposomes, through 2014 ($ Millions)
    • Figure 26 Total Global Sales of Liposomes, 2007-2014 ($ Millions)
    • Market Overview
    • Nanoparticles
    • Market Size
    • Table 68 Global Sales of Nanoparticles, through 2014 ($ Millions)
    • Figure 27 Global Sales of Nanoparticles, 2007-2014 ($ Millions)
    • Market Overview
    • Polymers
    • Market Size
    • Table 69 Global Sales of Polymers, through 2014 ($ Millions)
    • Figure 28 Global Sales of Polymers, 2007-2014 ($ Millions)
    • Market Overview
    • Pegylated Drug Delivery
    • Market Size
    • Table 70 Global Sales of Pegylated Drug Delivery, through 2014 ($ Millions)
    • Figure 29 Total Global Sales of Pegylated Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Monoclonal Antibodies
    • Market Size
    • Table 71 Global Sales of Monoclonal Antibodies, through 2014 ($ Millions)
    • Figure 30 Total Global Sales of Monoclonal Antibodies, 2007-2014 ($ Millions)
    • Market Overview
    • Buccal Drug Delivery
    • Market Size
    • Table 72 Global Sales of Buccal Drug Delivery, Though 2014 ($ Millions)
    • Figure 31 Total Global Sales of Buccal Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Rectal Drug Delivery
    • Market Size
    • Table 73 Global Sales of Rectal Drug Delivery, through 2014 ($ Millions)
    • Figure 32 Total Global Sales of Rectal Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Ocular Drug Delivery
    • Market Size
    • Table 74 Global Sales of Ocular Drug Delivery, through 2014 ($ Millions)
    • Figure 33 Total Global Sales of Ocular Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Vaginal Drug Delivery
    • Market Size
    • Table 75 Global Sales of Vaginal Drug Delivery, through 2014 ($ Millions)
    • Figure 34 Total Global Sales of Vaginal Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Inhalation Drug Delivery
    • Market Size
    • Table 76 Global Sales of Inhalation Drug Delivery, through 2014 ($ Millions)
    • Figure 35 Total Global Sales of Inhalation Drug Delivery, 2007-2014 ($ Millions)
    • Market Overview
    • Market Overview (Continued) 103
  • Chapter-8: Market Analysis
  • Chapter-9: New Developments
    • Table 77 Developments in Sustained-Release Oral Dosage Forms
    • Table 77 (Continued)
    • Table 78 Developments in Sustained-Release Injectable Dosage Forms
    • Table 78 (Continued)
    • Table 79 Developments in Sustained-Release Topical Dosage Forms
    • Table 80 Developments in Prodrugs
    • Table 80 (Continued)
    • Table 81 Developments in Implants and Iuds
    • Table 81 (Continued)
    • Table 82 Developments in Transdermal Drug Delivery Systems
    • Table 82 (Continued)
    • Table 83 Developments in Liposomal Delivery
    • Table 83 (Continued)
    • Table 84 Developments in Pegylated Drug Delivery
    • Table 84 (Continued)
    • Table 85 Developments in Nanoparticle Drug Delivery
    • Table 86 Developments in Monoclonal Antibodies
    • Table 86 (Continued)
    • Table 87 Developments in Buccal Drug Delivery
    • Table 88 Developments in Vaginal Drug Delivery
    • Table 89 Developments in Rectal Drug Delivery
    • Table 90 Developments in Inhalation Drug Delivery
    • Table 90 (Continued) 116
  • Chapter-10: Market by Therapeutic Areas
    • Market Size
    • Table 91 Global Sales of Drug Delivery Systems in Each Therapeutic Area, through 2014 ($ Billions)
    • Table 91 (Continued)
    • Figure 36 Global Sales of Drugs to Treat Liver Diseases, 2007-014 ($ Billions)
    • Market Share
    • Table 92 Share of Drug Delivery Systems in Therapeutic Areas, 2008 (%)
    • Figure 37 Share of Drug Delivery Systems in Therapeutic Areas, 2008 (%)
    • Cardiovascular Diseases
    • Market Size
    • Table 93 Global Sales of Drug Delivery Systems in Cardiovascular Diseases, through 2004 ($ Billions)
    • Figure 38 Global Sales of Drug Delivery Systems in Cardiovascular Diseases, 2007-2014 ($ Billions)
    • Oncology
    • Market Size
    • Table 94 Global Sales of Drug Delivery Systems in Oncology, through 2014 ($ Billions)
    • Figure 39 Global Sales of Drug Delivery Systems in Oncology, 2007-2014 ($ Billions)
    • Gastrointestinal
    • Market Size
    • Table 95 Global Sales of Drug Delivery Systems in Gastrointestinal Disorders, through 2014 ($ Billions)
    • Figure 40 Global Sales of Drug Delivery Systems in Gastrointestinal Disorders, 2007-2014 ($ Billions)
    • Urology
    • Market Size
    • Table 96 Global Sales of Drug Delivery Systems in Urology, through 2014 ($ Billions)
    • Figure 41 Global Sales of Drug Delivery Systems in Urology, 2007-2014 ($ Billions)
    • Diabetes
    • Market Size
    • Table 97 Global Sales of Drug Delivery Systems in Diabetic Market, through 2014 ($ Billions)
    • Figure 42 Global Sales of Drug Delivery Systems in Diabetic Market, 2007-2014 ($ Billions)
    • Central Nervous System Disorder
    • Market Size
    • Table 98 Global Sales of Drug Delivery Systems in Centeral Nervous System Market, through 2014 ($ Billions)
    • Figure 42 Global Sales of Drug Delivery Systems in Central Nervous System Market, 2007-2014 ($ Billions)
    • Respiratory Drug Delivery Systems
    • Market Size
    • Table 99 Global Sales of Drug Delivery Systems in Respiratory Diseases, through 2014 ($ Billions)
    • Figure 44 Global Sales of Drug Delivery Systems in Rispiratory Diseases, 2007-2014 ($ Billions)
    • Inflammatory Diseases and Allergy
    • Market Size
    • Table 100 Global Sales of Drug Delivery Systems in Inflammatory and Allergy, 2007-2014 ($ Billions)
    • Figure 45 Global Sales of Drug Delivery Systems in Inflammatory and Allergy Diseases, 2007-2014 ($ Billions)
    • Ophthalmology
    • Market Size
    • Table 101 Global Sales of Drug Delivery Systems in Ophthalmology, through 2014 ($ Billions)
    • Figure 46 Global Sales of Drug Delivery Systems in Ophthalmology, 2007-2014 ($ Billions)
    • Viral and Bacterial Diseases
    • Market Size
    • Table 102 Global Sales of Drug Delivery Systems in Viral and Bacterial Diseases, through 2014 ($ Billions)
    • Figure 47 Global Sales of Drug Delivery Systems in Viral and Bacterial Diseases, 2007-2014 ($ Billions)
    • Hormone Replacement Therapy (Hrt) and Gynecology
    • Market Size
    • Table 103 Global Sales of Drug Delivery Systems in Hormone Replacement Therapy and Gynecology, through 2014 ($ Billions)
    • Figure 48 Global Sales of Drug Delivery Systems in Hormone Replacement Therapy and Gynecology, 2007-2014 ($ Billions)
    • Others
    • Market Size
    • Table 104 Global Sales of Drug Delivery Systems in Other Therapeutic Areas and Technologies, through 2014 ($ Billions)
    • Figure 49 Global Sales of Drug Delivery Systems in Other Therapeutic Areas and Technologies, 2007-2014 ($ Billions) 135
  • Chapter-11: Patent Analysis
    • Patents by Year
    • Table 105 Total Number of Patents in Each Year, 2005-2009
    • Figure 50 Number of Patents, 2005-2009
    • Patents by Type
    • Table 106 Number of Patents by Type, 2005-2009
    • Figure 51 Number of Patents by Type, 2005-2009
    • Figure 52 Total Number of Patents, Share by Type, 2005-2009 (%)
    • Patents by Country
    • Table 107 Total Number of Patents by Country, 2005-2009
    • Figure 53 Total Number of Patents by Country, 2005-2009
    • Patents by Company
    • Table 108 Number of Patents by Company, 2005-2009
    • Table 108 (Continued)
    • Table 108 (Continued)
    • Figure 54 Number of Patents by Company, 2005-2009
    • Patents by Assignee
    • Table 109 Number of Patents by Assignee, 2005-2009
    • Figure 55 Number of Patents by Assignee, 2005-2009 146
  • Chapter-12: Company Profiles
    • Abbott Laboratories
    • Abraxis Bioscience, Inc
    • Akela Pharma
    • Akorn, Inc
    • Alcon, Inc
    • Alexion Pharmaceuticals
    • Alkermes, Inc
    • Allergan
    • Alpharx
    • Amgen
    • Antigenics
    • A P Pharma
    • Astellas Pharma
    • Astrazeneca
    • Aton Pharma
    • Barr Pharmaceuticals, Inc
    • Baxter
    • Bayer Healthcare
    • Biogen Idec
    • Biosante Pharmaceuticals, Inc
    • Biovail
    • Boehringer Ingelheim
    • Bristol Myers Squibb
    • Centocor
    • Cephalon Inc
    • Columbia Labs
    • Diatos Sa
    • Eisai Co
    • Elan
    • Enzon
    • Eurand N.V
    • Genentech
    • Generex Biotech
    • Genzyme
    • Gilead Sciences, Inc
    • Glaxosmithkline Plc
    • Imclone Systems
    • Johnson and Johnson
    • King Pharmaceuticals
    • K.V. Pharmaceutical Co
    • Lavipharm Corporation
    • 3m Company
    • Merck & Co
    • Mylan Laboratories, Inc
    • Nektar Therapeutics
    • Noven Pharmaceuticals, Inc
    • Novartis Ag
    • Novavax, Inc
    • Nycomed US, Inc
    • Osi Pharmaceuticals, Inc
    • Par Pharmaceutical Companies, Inc
    • Pdl Biopharma, Inc
    • Pfizer Inc
    • Qlt, Inc
    • Roche
    • Sanofi-Aventis
    • Schering-Plough
    • Teva Pharmaceutical Industries, Ltd
    • Watson Pharmaceuticals, Inc
    • Wyeth, Inc. 174
  • Appendix: Abbreviations
    • Abbreviations
    • Appendix (Continued) 176